The DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.
Therapeutic miRNA and siRNA: Moving from Bench to Clinic as Next Generation Medicine
Open accessAbstract
In the past few years, therapeutic microRNA (miRNA) and small interfering RNA (siRNA) are some of the most important biopharmaceuticals that are in commercial space as future medicines. This review summarizes the patents of miRNA- and siRNA-based new drugs, and also provides a snapshot about significant biopharmaceutical companies that are investing for the therapeutic development of miRNA and siRNA molecules. An insightful view about individual siRNA and miRNA drugs has been depicted with their present status, which is gaining attention in the therapeutic landscape. The efforts of the biopharmaceuticals are discussed with the status of their preclinical and/or clinical trials. Here, some of the setbacks have been highlighted during the biopharmaceutical development of miRNA and siRNA as individual therapeutics. Finally, a snapshot is illustrated about pharmacokinetics, pharmacodynamics with absorption, distribution, metabolism, and excretion (ADME), which is the fundamental development process of these therapeutics, as well as the delivery system for miRNA- and siRNA-based drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans
Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E., & Mello, C. C. (1998) · Nature · doi:10.1038/35888 · Cited by 15,429
The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14
Lee, R. C., Feinbaum, R. L., & Ambros, V. (1993) · Cell · doi:10.1016/0092-8674(93)90529-y · Cited by 12,948
The functions of animal microRNAs
Ambros, V. (2004) · Nature · doi:10.1038/nature02871 · Cited by 10,728
Calin, G. A., Dumitru, C. D., Shimizu, M., Bichi, R., Zupo, S., Noch, E., Aldler, H., Rattan, S., Keating, M., Rai, K., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.242606799 · Cited by 5,111
The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans
Reinhart, B. J., Slack, F. J., Basson, M., Pasquinelli, A. E., Bettinger, J. C., Rougvie, A. E., Horvitz, H. R., & Ruvkun, G. (2000) · Nature · doi:10.1038/35002607 · Cited by 4,981
Silencing of microRNAs in vivo with ‘antagomirs’
Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., & Stoffel, M. (2005) · Nature · doi:10.1038/nature04303 · Cited by 3,949
miRBase: integrating microRNA annotation and deep-sequencing data
Kozomara, A., & Griffiths-Jones, S. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq1027 · Cited by 3,634
Acute Kidney Injury, Mortality, Length of Stay, and Costs in Hospitalized Patients
Chertow, G. M., Burdick, E., Honour, M., Bonventre, J. V., & Bates, D. W. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004090740 · Cited by 3,408
Non-coding RNAs and cancer: microRNAs and beyond
Raia, R. M., & Calin, G. A. (2011) · Journal of Nucleic Acids Investigation · doi:10.4081/jnai.2011.e5 · Cited by 3,382
Membrane transporters in drug development
The International Transporter Consortium, Giacomini, K. M., Huang, S.-M., Tweedie, D. J., Benet, L. Z., Brouwer, K. L. R., Chu, X., Dahlin, A., Evers, R., Fischer, V., et al. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3028 · Cited by 3,340
An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells
Hammond, S. M., Bernstein, E., Beach, D., & Hannon, G. J. (2000) · Nature · doi:10.1038/35005107 · Cited by 3,003
Biogenesis of small RNAs in animals
Kim, V. N., Han, J., & Siomi, M. C. (2009) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2632 · Cited by 2,814
Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA
Pasquinelli, A. E., Reinhart, B. J., Slack, F., Martindale, M. Q., Kuroda, M. I., Maller, B., Hayward, D. C., Ball, E. E., Degnan, B., Müller, P., et al. (2000) · Nature · doi:10.1038/35040556 · Cited by 2,565
Mechanisms of gene silencing by double-stranded RNA
Meister, G., & Tuschl, T. (2004) · Nature · doi:10.1038/nature02873 · Cited by 2,539
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
Davis, M. E., Zuckerman, J. E., Choi, C. H. J., Seligson, D., Tolcher, A., Alabi, C. A., Yen, Y., Heidel, J. D., & Ribas, A. (2010) · Nature · doi:10.1038/nature08956 · Cited by 2,505
Treatment of HCV Infection by Targeting MicroRNA
Janssen, H. L. A., Reesink, H. W., Lawitz, E. J., Zeuzem, S., Rodriguez-Torres, M., Patel, K., van der Meer, A. J., Patick, A. K., Chen, A., Zhou, Y., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209026 · Cited by 2,204
Control of Stress-Dependent Cardiac Growth and Gene Expression by a MicroRNA
van Rooij, E., Sutherland, L. B., Qi, X., Richardson, J. A., Hill, J., & Olson, E. N. (2007) · Science · doi:10.1126/science.1139089 · Cited by 1,657
LNA-mediated microRNA silencing in non-human primates
Elmén, J., Lindow, M., Schütz, S., Lawrence, M., Petri, A., Obad, S., Lindholm, M., Hedtjärn, M., Hansen, H. F., Berger, U., et al. (2008) · Nature · doi:10.1038/nature06783 · Cited by 1,589 · cited 4×
“In other study, Elmén et al.(76,77) used single LNA-anti-miR i.”
BackgroundMethodInfluentialRNAi-mediated gene silencing in non-human primates
Zimmermann, T. S., Lee, A. C. H., Akinc, A., Bramlage, B., Bumcrot, D., Fedoruk, M. N., Harborth, J., Heyes, J. A., Jeffs, L. B., John, M., et al. (2006) · Nature · doi:10.1038/nature04688 · Cited by 1,357 · cited 2×
“ApoB-specific siRNAs were encoded in SNALPs.46 Tekmira Pharmaceuticals initiated a phase 1 clinical trial by enrolling 23 adult Molecular Therapy: Nucleic Acids Vol. 8 September 2017 137 volunteers with mild hypercholesterolemia.”
MethodLipid-like materials for low-dose, in vivo gene silencing
Love, K. T., Mahon, K. P., Levins, C. G., Whitehead, K. A., Querbes, W., Dorkin, J. R., Qin, J., Cantley, W., Qin, L. L., Racie, T., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910603106 · Cited by 969
RNA-Based Therapeutics: Current Progress and Future Prospects
Burnett, J. C., & Rossi, J. J. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.12.008 · Cited by 819
Delivery of siRNA Therapeutics: Barriers and Carriers
Wang, J., Lu, Z., Wientjes, M. G., & Au, J. L.-S. (2010) · The AAPS Journal · doi:10.1208/s12248-010-9210-4 · Cited by 798
Tabernero, J., Shapiro, G. I., LoRusso, P. M., Cervantes, A., Schwartz, G. K., Weiss, G. J., Paz-Ares, L., Cho, D. C., Infante, J. R., Alsina, M., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0429 · Cited by 698
Elmén, J., Lindow, M., Silahtaroglu, A., Bak, M., Christensen, M., Lind-Thomsen, A., Hedtjärn, M., Hansen, J. B., Hansen, H. F., Straarup, E. M., et al. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkm1113 · Cited by 672
Cytochrome P450s and other enzymes in drug metabolism and toxicity
Guengerich, F. P. (2006) · The AAPS Journal · doi:10.1208/aapsj080112 · Cited by 624
Therapeutic Inhibition of miR-208a Improves Cardiac Function and Survival During Heart Failure
Montgomery, R. L., Hullinger, T. G., Semus, H. M., Dickinson, B. A., Seto, A. G., Lynch, J. M., Stack, C., Latimer, P. A., Olson, E. N., & van Rooij, E. (2011) · Circulation · doi:10.1161/circulationaha.111.030932 · Cited by 603
MicroRNA-21 Promotes Fibrosis of the Kidney by Silencing Metabolic Pathways
Chau, B. N., Xin, C., Hartner, J., Ren, S., Castano, A. P., Linn, G., Li, J., Tran, P. T., Kaimal, V., Huang, X., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003205 · Cited by 587
Inhibition of microRNA function by antimiR oligonucleotides
Stenvang, J., Petri, A., Lindow, M., Obad, S., & Kauppinen, S. (2012) · Silence · doi:10.1186/1758-907x-3-1 · Cited by 560
Troppmann, C., Gillingham, K. J., Benedetti, E., Almond, P. S., Gruessner, R. W. G., Najarian, J. S., & Matas, A. J. (1995) · Transplantation · doi:10.1097/00007890-199504150-00007 · Cited by 508
An analysis of the critical role of public science in innovation: the case of biotechnology
McMillan, G. S., Narin, F., & Deeds, D. L. (2000) · Research Policy · doi:10.1016/s0048-7333(99)00030-x · Cited by 479
Vive la différence: biogenesis and evolution of microRNAs in plants and animals
Axtell, M. J., Westholm, J. O., & Lai, E. C. (2011) · Genome Biology · doi:10.1186/gb-2011-12-4-221 · Cited by 477
First microRNA mimic enters clinic
Bouchie, A. (2013) · Nature Biotechnology · doi:10.1038/nbt0713-577 · Cited by 472
Specificity, duplex degradation and subcellular localization of antagomirs
Krützfeldt, J., Kuwajima, S., Braich, R., Rajeev, K. G., Pena, J., Tuschl, T., Manoharan, M., & Stoffel, M. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm024 · Cited by 455
Developing MicroRNA Therapeutics
van Rooij, E., Purcell, A. L., & Levin, A. A. (2012) · Circulation Research · doi:10.1161/circresaha.111.247916 · Cited by 449
Levin, A. A. (1999) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(99)00140-2 · Cited by 438
Gomez, I. G., MacKenna, D. A., Johnson, B. G., Kaimal, V., Roach, A. M., Ren, S., Nakagawa, N., Xin, C., Newitt, R., Pandya, S., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci75852 · Cited by 413
Broderick, J. A., & Zamore, P. D. (2011) · Gene Therapy · doi:10.1038/gt.2011.50 · Cited by 388
Heidel, J. D., Yu, Z., Liu, J. Y.-C., Rele, S. M., Liang, Y., Zeidan, R. K., Kornbrust, D. J., & Davis, M. E. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701458104 · Cited by 382
Miravirsen (SPC3649) can inhibit the biogenesis of miR-122
Gebert, L. F. R., Rebhan, M. A. E., Crivelli, S. E. M., Denzler, R., Stoffel, M., & Hall, J. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt852 · Cited by 364
A Cardiac MicroRNA Governs Systemic Energy Homeostasis by Regulation of MED13
Grueter, C. E., van Rooij, E., Johnson, B. A., DeLeon, S. M., Sutherland, L. B., Qi, X., Gautron, L., Elmquist, J. K., Bassel-Duby, R., & Olson, E. N. (2012) · Cell · doi:10.1016/j.cell.2012.03.029 · Cited by 364
The miR-144/451 locus is required for erythroid homeostasis
Rasmussen, K. D., Simmini, S., Abreu-Goodger, C., Bartonicek, N., Di Giacomo, M., Bilbao-Cortes, D., Horos, R., Von Lindern, M., Enright, A. J., & O’Carroll, D. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100458 · Cited by 330
Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma
Zhang, K., Zhang, L., & Weinreb, R. N. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3745 · Cited by 316
Discovering the first microRNA-targeted drug
Lindow, M., & Kauppinen, S. (2012) · Journal of Cell Biology · doi:10.1083/jcb.201208082 · Cited by 302
A positive feedback between p53 and miR-34 miRNAs mediates tumor suppression
Okada, N., Lin, C.-P., Ribeiro, M. C., Biton, A., Lai, G., He, X., Bu, P., Vogel, H., Jablons, D. M., Keller, A. C., et al. (2014) · Genes & Development · doi:10.1101/gad.233585.113 · Cited by 297
A status report on RNAi therapeutics
Vaishnaw, A. K., Gollob, J., Gamba-Vitalo, C., Hutabarat, R., Sah, D., Meyers, R., de Fougerolles, T., & Maraganore, J. (2010) · Silence · doi:10.1186/1758-907x-1-14 · Cited by 297
RNAi and small interfering RNAs in human disease therapeutic applications
Lares, M. R., Rossi, J. J., & Ouellet, D. L. (2010) · Trends in biotechnology · doi:10.1016/j.tibtech.2010.07.009 · Cited by 277
Schultheis, B., Strumberg, D., Santel, A., Vank, C., Gebhardt, F., Keil, O., Lange, C., Giese, K., Kaufmann, J., Khan, M., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.55.0376 · Cited by 260
DEVINCENZO, J., CEHELSKY, J., ALVAREZ, R., ELBASHIR, S., HARBORTH, J., TOUDJARSKA, I., NECHEV, L., MURUGAIAH, V, VLIET, A., & VAISHNAW, A. (2008) · Antiviral Research · doi:10.1016/j.antiviral.2007.11.009 · Cited by 247
The Role of Public-Sector Research in the Discovery of Drugs and Vaccines
Stevens, A. J., Jensen, J. J., Wyller, K., Kilgore, P. C., Chatterjee, S., & Rohrbaugh, M. L. (2011) · New England Journal of Medicine · doi:10.1056/nejmsa1008268 · Cited by 244
US biopharmaceutical finance and the sustainability of the biotech business model
Lazonick, W., & Tulum, Ö. (2011) · Research Policy · doi:10.1016/j.respol.2011.05.021 · Cited by 217
US Biopharmaceutical Finance and the Sustainability of the Biotech Business Model
Lazonick, W., & Tulum, O. (2011) · SSRN Electronic Journal · doi:10.2139/ssrn.2257932 · Cited by 199
Pharmacokinetics in Drug Discovery
Ruiz-Garcia, A., Bermejo, M., Moss, A., & Casabo, V. G. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21009 · Cited by 199
Clinical applications of microRNAs
Hydbring, P., & Badalian‐Very, G. (2013) · F1000Research · doi:10.12688/f1000research.2-136.v3 · Cited by 192
Defective erythroid differentiation in miR-451 mutant mice mediated by 14-3-3ζ
Patrick, D. M., Zhang, C. C., Tao, Y., Yao, H., Qi, X., Schwartz, R. J., Jun-Shen Huang, L., & Olson, E. N. (2010) · Genes & Development · doi:10.1101/gad.1942810 · Cited by 178
Heidel, J. D., Liu, J. Y.-C., Yen, Y., Zhou, B., Heale, B. S. E., Rossi, J. J., Bartlett, D. W., & Davis, M. E. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2218 · Cited by 160
Lindholm, M., Elmén, J., Fisker, N., Hansen, H. F., Persson, R., Møller, M. R., Rosenbohm, C., Ørum, H., Straarup, E. M., & Koch, T. (2011) · Molecular Therapy · doi:10.1038/mt.2011.260 · Cited by 158
Guidelines for Antisense Oligonucleotide Design and Insight Into Splice-modulating Mechanisms
Aartsma-Rus, A. M., van Vliet, L., Hirschi, M., Janson, A. A. M., Heemskerk, H., de Winter, C. L., de Kimpe, S. J., van Deutekom, J. C. T., Hoen, P. A. C. ’., & van Ommen, G. B. (2008) · Molecular Therapy · doi:10.1038/mt.2008.205 · Cited by 147
Clinical applications of microRNAs
Hydbring, P., & Badalian‐Very, G. (2013) · F1000Research · doi:10.12688/f1000research.2-136.v1 · Cited by 140
RRM2 Regulates Bcl-2 in Head and Neck and Lung Cancers: A Potential Target for Cancer Therapy
Rahman, M. A., Amin, A. R. M. R., Wang, D., Koenig, L., Nannapaneni, S., Chen, Z., Wang, Z., Sica, G., Deng, X., Chen, Z., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0073 · Cited by 129
Bevasiranib for the Treatment of Wet, Age-Related Macular Degeneration
Garba, A. O., & Mousa, S. A. (2010) · Ophthalmology and Eye Diseases · doi:10.4137/oed.s4878 · Cited by 126
Functional Nanostructures for Effective Delivery of Small Interfering RNA Therapeutics
Hong, C. A., & Nam, Y. S. (2014) · Theranostics · doi:10.7150/thno.8491 · Cited by 126
Atu027 Prevents Pulmonary Metastasis in Experimental and Spontaneous Mouse Metastasis Models
Santel, A., Aleku, M., Röder, N., Möpert, K., Durieux, B., Janke, O., Keil, O., Endruschat, J., Dames, S., Lange, C. M., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1994 · Cited by 107
Nguyen, Q. D., Schachar, R. A., Nduaka, C. I., Sperling, M., Basile, A. S., Klamerus, K. J., Chi-Burris, K., Yan, E., Paggiarino, D. A., Rosenblatt, I., et al. (2012) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.12-9961 · Cited by 101
The Business of RNAi Therapeutics in 2012
Haussecker, D. (2012) · Molecular Therapy: Nucleic Acids · doi:10.1038/mtna.2011.9 · Cited by 93
The Business of RNAi Therapeutics
Haussecker, D. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.007 · Cited by 87
Watts, J. K., & Corey, D. R. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.03.109 · Cited by 62
Methylation-associated silencing of microRNA-34b in hepatocellular carcinoma cancer
Xie, K., Liu, J., Chen, J., Dong, J., Ma, H., Liu, Y., & Hu, Z. (2014) · Gene · doi:10.1016/j.gene.2014.03.059 · Cited by 59
Caldwell, G. W. (2010) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/978160805204210401010607 · Cited by 55
RNA Interference: Mechanisms, Technical Challenges, and Therapeutic Opportunities
Sioud, M. (2014) · Methods in molecular biology · doi:10.1007/978-1-4939-1538-5_1 · Cited by 55
Absorption of Antisense Oligonucleotides in Rat Intestine: Effect of Chemistry and Length
Khatsenko, O. G., MORGAN, R., Truong, L., York-DeFalco, C., Sasmor, H. M., Conklin, B., & Geary, R. S. (2000) · Antisense and Nucleic Acid Drug Development · doi:10.1089/oli.1.2000.10.35 · Cited by 51
RNA interference: potential therapeutic targets
Jana, S., Chakraborty, C., Nandi, S., & Deb, J. K. (2004) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-004-1732-1 · Cited by 46
Self-citationMicro-RNA-122 levels in acute liver failure and chronic hepatitis C
Dubin, P. H., Yuan, H., Devine, R. K., Hynan, L. S., Jain, M. K., Lee, W. M., & the Acute Liver Failure Study Group (2014) · Journal of Medical Virology · doi:10.1002/jmv.23987 · Cited by 40
Hanout, M., Ferraz, D., Ansari, M., Maqsood, N., Kherani, S., Sepah, Y. J., Rajagopalan, N., Ibrahim, M., Diana, V., & Nguyen, Q. D. (2013) · BioMed Research International · doi:10.1155/2013/830837 · Cited by 40
Delivery of RNAi therapeutics: work in progress
Miller, A. D. (2013) · Expert Review of Medical Devices · doi:10.1586/17434440.2013.855471 · Cited by 33
Hennessy, E. J., & Moore, K. J. (2013) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e31829d48bf · Cited by 31
The 'real world' utility of miRNA patents: lessons learned from expressed sequence tags
McLeod, B. W., Hayman, M. L., Purcell, A. L., Marcus, J. S., & Veitenheimer, E. E. (2011) · Nature Biotechnology · doi:10.1038/nbt.1765 · Cited by 19
Rasmussen, K. D., & O’Carroll, D. (2011) · Blood · doi:10.1182/blood-2011-04-350728 · Cited by 18
Targeting microRNA-122: Walking on cutting edge of hepatitis C virus infection therapy
Motavaf, M., Safari, S., & Alavian, S. M. (2014) · Acta Virologica · doi:10.4149/av_2014_04_301 · Cited by 12
Tapper, E. B., Patwardhan, V. R., & Curry, M. P. (2014) · Digestive Diseases and Sciences · doi:10.1007/s10620-014-3490-y · Cited by 8
Wang, X., Yan, F., Du, Q., & Liang, Z. (2010) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2010.11.011 · Cited by 2
Cited by
Ratti, M., Lampis, A., Ghidini, M., Salati, M., Mirchev, M. B., Valeri, N., & Hahne, J. C. (2020) · Targeted Oncology · doi:10.1007/s11523-020-00717-x · Cited by 606
Peptide and protein nanoparticle conjugates: versatile platforms for biomedical applications
Spicer, C. D., Jumeaux, C., Gupta, B., & Stevens, M. M. (2018) · Chemical Society Reviews · doi:10.1039/c7cs00877e · Cited by 497
NLRP3 inflammasome in endothelial dysfunction
Bai, B., Yang, Y., Wang, Q., Li, M., Tian, C., Liu, Y., Aung, L. H. H., Li, P.-F., Yu, T., & Chu, X.-M. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-02985-x · Cited by 491
METTL1 Promotes let-7 MicroRNA Processing via m7G Methylation
Pandolfini, L., Barbieri, I., Bannister, A. J., Hendrick, A., Andrews, B., Webster, N., Murat, P., Mach, P., Brandi, R., Robson, S. C., et al. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.03.040 · Cited by 491
Cheng, L., Albers, P., Berney, D. M., Feldman, D. R., Daugaard, G., Gilligan, T., & Looijenga, L. H. J. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0029-0 · Cited by 462
Metadata
- Authors
- Chakraborty, C., Sharma, A. R., Sharma, G., Doss, C. G. P., & Lee, S.-S.
- Venue
- Molecular Therapy - Nucleic Acids
- Publisher
- Elsevier BV
- Published
- 2017-09
- Volume
- 8
- Pages
- 132-143
- ISSN
- 2162-2531 (ISSN-L)
- OpenAlex
- W2624827575
- Cited by
- 731
- References
- 80
- FWCI
- 39.31
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.